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Successful Use of Recombinant Tissue Plasminogen Activator in a
Patient With Relapsing Peritonitis
John M. Duch, MD, and Jerry Yee, MD
• Intraperitoneal (IP) administration of either streptokinase (SK) or urokinase (UK) has assumed an adjunctive role
to antibiotic therapy in selected patients with relapsing peritonitis. In these circumstances, bacteria may be
protected from antibiotics through sequestration in either fibrinous structures or biofilms within the lumen of the
peritoneal dialysis (PD) catheter or the peritoneal cavity. In some cases, it appears that disruption of these sheltered
microenvironments by thrombolytic agents facilitated eradication of the offending organism and obviated the need
for catheter removal, replacement, or interim hemodialysis. Although IP SK has been generally well tolerated as
additive therapy in relapsing peritonitis, sporadic reports of significant complications, such as abdominal pain,
fever, and severe hypotension, have precluded its more widespread acceptance. The only other thrombolytic agent
used in this setting, UK, is presently unavailable because of a manufacturing shortfall. Therefore, adjunctive
thrombolytic therapy for relapsing peritonitis is currently restricted. To circumvent these limitations, we devised an
IP tissue plasminogen activator (tPA) protocol to eliminate recurring infection in a patient undergoing chronic
ambulatory PD. After a third episode of peritonitis caused by Enterobactercloacae, treated twice previously with an
adequate antibiotic regimen, we instilled 6 mL of tPA (1 mg/mL) into the PD catheter for a 2-hour dwell time. The
treatment was well tolerated and, in conjunction with a third course of antibiotic therapy, has produced an
infection-free interval of 8 months.
© 2001 by the National Kidney Foundation, Inc.
INDEX WORDS: Continuous ambulatory peritoneal dialysis (CAPD); peritonitis; tissue plasminogen activator (tPA).
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~ERITONITIS IS a serious complication for
patients who undergo peritoneal dialysis
(PD) as treatment of end-stage renal disease that
frequently leads to hospitalization, catheter loss,
and technique failure. ~Afflicted patients usually
present with abdominal pain and/or cloudy effluent. The white blood cell count in the effluent is
usually 100//xL or greater, with at least 50%
polymorphonuclear neutrophilsJ -5 Relapsing or
recurrent peritonitis has been defined as a second
episode of peritonitis caused by the identical
organism that caused the immediately preceding
infection and that arises within 2 to 4 weeks of
discontinuing antibiotic therapy.l,2 In addition to
standard antimicrobial regimens, management of
these cases involves a thorough search for a
source(s) of relapsing infection and careful consideration of PD catheter removal (Table 1). ~-7
Intraperitoneal (IP) thrombolytic drugs have
been used successfully as a last pharmacological
maneuver in some of these patients before resorting to PD catheter removal. To date, only streptokinase (SK) and urokinase (UK) have been
used in this particular catheter salvage procedure. Presently, tissue plasminogen activator (tPA)
is being used with increasing frequency in dialysis patients to declot thrombosed polytetrafluoroethylene grafts and restore and preserve the function of tunneled silastic elastomer hemodialysis
catheters (A. Graham, personal communication,

October 1999). 8,9Although IP tPA administration
has not been reported in humans, it has been
safely used in several animal species. ~0-Js
We were confronted with a therapeutic dilemma when a previously healthy patient undergoing continuous ambulatory PD presented with
a third episode of relapsing peritonitis without a
clear indication for catheter removal. In an attempt to eradicate infection and preserve his PD
catheter, we used IP tPA as a therapeutic adjunct
to directed antimicrobial therapy.

CASE REPORT
A 3l-year-oldblack man undergoingcontinuousambulatory PD presented with three episodes of peritonitis within2
months. Selected relevant clinical information from each
episode is listed in Table 2. The index infection manifested 2
days after the patient bathed in tap water without protecting

From the Department of Medicine, Wright-PattersonMedical Center, Wright-Patterson Air Force Base, OH; and the
Department of Medicine, Henry Ford Hospital, Detroit, ML
Received February 29, 2000; accepted in revised form
August 18, 2000.
The opinions expressed are solely those of the authors and
do not reflect the officialpolicy ~f the Department of Defense
or other departments of the US Government.
Address reprint requests to John M. Duch, MD, 74 MDOS/
SGOMK, 4881 Sugar Maple Dr, Wright-PattersonAFB, OH
45433-5529. E-mail: john.duch@wpafb.afmil
© 2001 by the National Kidney Foundation, Inc.
0272-6386/01/3701-002153.00/0
doi: 10.1053/ajkd.2001.20609

American Journal of Kidney Diseases, Vo137, No 1 (January), 2001 : pp 149-153

149

150
Table 1.

DUCHANDYEE
Indications for Early Catheter Withdrawal in
Relapsing Peritonitis

Concurrent tunnel infection or certain exit-site infections
Coexisting intra-abdominal abscesses
Identification of certain pathogens (fungi, Pseudomonas
species, Xanthomonas species, anaerobes,
mycobacteria)
Failure to respond to initial therapy or clinical deterioration
after therapy is initiated
Relapsing peritonitis of no apparent cause
NOTE. Recommendations from Piraino, 1 Keane et al,2
and Tzamaloukas.4

the catheter. He rapidly responded to therapy at another
institution with IP vancomycin and gentamicin and remained on this therapy for 2 weeks because of negative
culture results. During a routine follow-up evaluation, he felt
well, and abdominal examination was unremarkable. Analysis of the PD effluent showed a normal cell count and
negative Gram stain results, but cultures of the effluent were
positive for Enterobacter cloacae. Daily treatment with IP
gentamicin was resumed for another 2 weeks, then discontinued. Two weeks later, he developed recurrent abdominal
pain and cloudy effluent (Table 2). Again, rapid improvement and recovery were achieved with IP vancomycin and
gentamicin. After the cultures showed positive results again
for E cloacae, therapy was consolidated to oral ciprofloxacin, based on culture sensitivity data. One week after completing the course of ciprofloxacin, a third episode of peritonitis was detected. After empiric therapy with one dose of IP
vancomycin and gentamicin, treatment was consolidated to
oral ciprofloxacin and IP cefepime after growth of E cloacae
was detected from the PD fluid.
At this time, the possibility of intermittent seeding of the
peritoneal cavity from an intraluminal catheter reservoir of
bacteria was considered. To avoid catheter removal, adjunctive therapy with an IP thrombolytic agent was considered.
After reviewing existing protocols for the use of thrombo-

Table 2.

Refined therapy

Time to relapse:l:

DISCUSSION

The index patient was an ideal candidate for
catheter salvage by thrombolytic therapy because there was no suspicion of recurrent breaches
of aseptic technique, no evidence of intraabdominal pathological states that would predispose to recurrent peritonitis, and no apparent
exit-site or tunnel infection. Other than the ex-

Characteristics of Three Episodes of Peritonitis

First Episode
PD effluent cell
count, differential
PD fluid culture
results
Empiric therapy*

lytic agents for dysfunctional hemodialysis and PD catheters
and relapsing peritonitis, informal discussions were conducted with technical support representatives of Genentech,
Inc (N San Francisco, CA), and a protocol was devised for
IP administration of tPA in the form of recombinant alteplase
(Activase; Genentech Inc).
Three weeks after therapy for the third episode of peritonitis had been initiated, the patient's abdomen was drained,
and 6 mL of recombinant alteplase (1 mg/mL) was injected
through the transfer set (priming volume, 1.8 mL) into the
patient's PD catheter (Cruz, Wheeling, IL; priming volume,
6 mL) and allowed to dwell for 2 hours with the catheter
clamped. The tPA was carefully aspirated, and a rapid
exchange of 1 L of PD fluid was performed. Next, a 2-L
exchange was performed immediately with 1 g of IP
cefepime, which was allowed to dwell for 6 hours to optimize the exposure of bacteria to the antibiotic. No adverse
reactions were observed within the immediate period of IP
thrombolytic administration or over the next 3 days, during
which time increased fibrin strands were detected in the PD
fluid. Specifically, there was no abdominal pain, fever, or
evidence of local or systemic bleeding. Three additional
weeks of therapy with IP cefepime and oral ciprofloxacin
were prescribed. Sampling of the effluent on the day of tPA
administration and 3, 5, 10, and 25 weeks later showed
normal results for cell analyses and negative culture results.
The patient remained clinically asymptomatic throughout
this period.

SecondEpisode

Third Episode

Not available

779 WBC//~L, 91%
neutrophils

1,500 WBC//~L, 75% neutrophils

Enterobacter cloacae

E cloacae

E cloacae

IP vancomycin, 2 doses;
IP gentamicin, 2 wk
IP gentamicin, additional
2 wk

IP vancomycin, 1 dose;
IP gentamicin, 1 wk
Ciprofloxacin 500 mg
PO BID, 1 wk

IP vancomycin, 1 dose; IP gentamicin,
1 dose
Ciprofloxacin 500 mg PO BID, 6 wk;
Cefepime 1 g IP QD, 6 wk; 6 mLtPA
(1 mg/mL) IP, one 2-h dwell1

2 wk

1 wk

Abbreviations: WBC, white blood cells; PO, orally; BID, twice daily; QD, daily.
*Adjunctive therapy with heparin, 1,000 U/L of PD fluid, was administered until effluent was clear.
l-See text for details.
:l:From the last dose of antibiotics.

IP tPA IN RELAPSING PERITONITIS

pected minor degree of drug adsorption to the
polyurethane catheter, we harbored no suspicion
that tPA would react adversely with the catheter
(T. Patapoff, personal communication, October
1999). Our patient had no relative or absolute
contraindications to local or systemic thrombolytic treatment.
One prospective study and several case reports
supported the use of either SK or UK as an
effective component of therapeutic regimens of
relapsing and/or resistant peritonitis. 19-28Presumably, the thrombolytic agent enables the eradication of infection through physical perturbation of
fibrin-coated microenvironments that shield the
offending organism. These bacteria, previously
sequestered from antibiotics, are thus rendered
susceptible to their microbicidal actions. 19-22.26,27
Alternatively, some bacteria may be protected
from antibiotics by their secretion of an exopolysaccharide layer of biofilm, which has been
shown on the inner aspect of peritoneal catheters
by electron microscopy. 29 In some instances, this
biofilm was postulated to be the source of relapsing infection and was also believed to contribute
to antibiotic resistance. 29-33 Although thrombolytic agents do not affect the growth of biofilm,
they may induce qualitative structural alterations
of the exopolysaccharide architecture that facilitate antibiotic penetration. 26 Thus, in appropriate
circumstances, IP instillation of thrombolytics
may spare patients the discomfort and expense of
repeated catheter implantation.19'22'26'27
Significant variability exists among published
protocols regarding thrombolytic therapy in patients with end-stage renal disease who undergo
either PD or hemodialysis. The indications for
treatment (eg, clotted hemodialysis catheter, obstructed PD catheter, and relapsing peritonitis),
type and dose of thrombolytic administered, infusate volume, and dosing interval vary widely.
For example, Pickering et a122 recommend instilling 7,500 IU of UK, diluted in 5 mL of saline,
into the PD catheter for a 2-hour dwell time for
selected individuals with relapsing peritonitis.
Others have injected 75,000 IU of UK into a 2-L
bag of dialysate and instilled the contents for 30
to 60 minutes into patients with relapsing peritonitis or, alternatively, injected the same amount
of UK mixed in 40 mL of diluent directly into the
PD catheter for an equivalent period to treat
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outflow obstruction. 24 Another group reported
success with a much lower dose of 5,000 IU of
UK in obstructed PD catheters. 25 The National
Kidney Foundation-Dialysis Outcomes Quality
Initiative guidelines for obstructed hemodialysis
catheters recommend that UK, 5,000 U/mL, be
instilled into each catheter lumen for a dwell
time of 30 minutes. 34 In the protocol of Paulsen
et al, 8 clotted hemodialysis catheters are injected
with tPA at a concentration of 1 mg/mL in
sufficient volumes to fill each catheter lumen and
left for varying periods of 30 minutes to 4 days
before removal. The regimen designed and implemented in our patient represents an amalgam of
these published protocols.
Adverse effects related to the IP administration of SK or UK have been infrequent and
mostly ascribed to SK. Importantly, there have
been no reports of systemic bleeding complications related to IP delivery of these drugs, including cases in which IP SK was used to restore
function of clotted PD catheters in patients who
developed active abdominal wall bleeding after
insertion of their PD catheters. 35-37The notation
that conventional laboratory parameters of hemostasis remain unaltered after IP SK and UK
administration suggests that these drugs are not
significantly absorbed across the peritoneal membrane. 36,38For this reason, some investigators no
longer routinely measure hemostasis parameters
during IP thrombolytic u s e . 24 Recombinant alteplase (molecular weight [MW], 65,000 d) is
larger than either UK (MW, 54,000 or 34,000 d)
or SK (MW, 47,000 d) and has a biological
half-life shorter than both, which implies its
favorable comparison to UK and SK regarding
the risk for inducing systemic hemorrhage during IP delivery.
IP tPA has been administered to animals to
reduce the development of postoperative adhesions and abscesses in models of peritonitis and
intra-abdominal injury. In all but one of the
investigations that we reviewed, IP tPA at doses
similar to or greater than that used in our patient
did not cause significant hemorrhagic complications in the rabbit, m-14 rat] 5-17 or dog. ~8 In one
study, 10 mg of IP tPA caused fatal intraabdominal hemorrhage after surgically induced
uterine trauma in several rabbits. 39 Because IP
tPA administration has not been studied in hu-
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mans, we recommend applying standard exclusion criteria used for systemic delivery of thrombolytic drugs to candidates for whom IP tPA is
being considered until further information becomes available.
The index patient sustained a 3-week delay
between the initiation of antibiotic therapy for
his third episode of peritonitis and treatment with
tPA because of the unavailability of UK and the
unwillingness of the patient to be administered
SK. Ideally, IP tPA should be implemented within
a few days of the diagnosis of relapsing peritonitis, and antibiotics should be continued for an
additional 2 to 4 weeks. We augmented the
provision of tPA with a daily dose of IP cefepime
in the hope that continuous incubation of the
catheter lumen in an antibiotic would synergize
with the disruption of a presumptive catheter
biofilm. Single daily dosing was preferred in
favor of a continual dosing schedule because of
patient-specific factors. Although ciprofloxacin
therapy may have been redundant in this case, it
was continued because of uncertainty regarding
the merits of daily versus continuous IP cephalosporin treatment of gram-negative bacillary relapsing infection.
In conclusion, the combination of IP tPA and
antibiotics was used to successfully treat a patient with relapsing peritonitis caused by E cloacae. We speculate that IP thrombolytic therapy
facilitated eradication of the infection and preserved this patient's peritoneal catheter. However, this point cannot be definitively concluded
because of the differences in choice, duration,
and modality of antibiotic administration in the
last peritonitis episode. Because of our success in
this case, we contend that use of adjunctive IP
tPA in carefully selected cases of relapsing peritonitis and/or obstructed PD catheters warrants
further investigation. Furthermore, we believe
that a randomized multicenter trial that directly
compares IP tPA with placebo or another thrombolytic agent(s) should be undertaken to clearly
define the safety and efficacy of IP tPA. Pretreatment and posttreatment parameters of hemostasis should also be incorporated into such trials.
REFERENCES

I. Piraino B: Peritonitis as a complication of peritoneal
dialysis. J Am Soc Nephrol 9:1956-1964, 1998
2. Keane WE Alexander SR, Bailie GR, Boeschoten E,

Gokal R, Golper TA, Holmes CJ, Huang C, Kawaguchi Y,
Piraino B, Riella M, Schafer E Vas S: Peritoneal dialysisrelated peritonitis treatment recommendations: 1996 Update. Perit Dial Int 16:557-573, 1996
3. Van Biesen W, Vanholder R, Volgelaers D, Peleman R,
Verschraegen G, Vijt D, Lameire N: The need for a centertailored treatment protocol for peritonitis. Petit Dial Int
18:274-28t, 1998
4. Tzamaloukas AH: Peritonitis in peritoneal dialysis
patients: An overview. Adv Ren Replace Ther 3:232-236,
1996
5. Pastan S, Bailey J: Dialysis therapy. N Engl J Med
338:1428-1437, 1998
6. Majkowski NL, Mendley SR: Simultaneous removal
and replacement of infected peritoneal dialysis catheters.
Am J Kidney Dis 29:706-711, 1997
7. Worland MA, Radabaugh RS, Mueller BA: Intraperitoheal thrombolytic therapy for peritoneal dialysis-associated
peritonitis. Ann Pharmacother 32:1216-1220, 1998
8. Paulsen D, Reisether A, Aasen M, Fauchald P: Use of
tissue plasminogen activator for reopening of clotted dialysis catheters. Nephron 64:468-470, 1993
9. Schenk P, Rosenkrantz AR, Wtlfl G, Htrl W, Traindl
O: Recombinant tissue plasminogen activator is a useful
alternative to heparin in priming Quinton Permcath. Am J
Kidney Dis 35:130-136, 2000
10. Menzies D, Ellis H: The role of tissue plasminogen
activator in adhesion prevention. Surg Gynecol Obstet 172:
362-366, 1991
11. Mohler M, Hollenbach S, Nguyen T, Reger V, Hotchkiss A: Effect of recombinant tissue-type plasminogen activator (r-tPA) on the prevention of intraabdominal adhesion
lbrmation. Thromb Haemost 54:270A, 1985 (abstr)
12. Dunn RC, Mohler M: Effect of varying days of tissue
plasminogen activator therapy on the prevention of postsurgical adhesions in a rabbit model. J Surg Res 54:242-245,
1993

13. Doody KJ, Dunn RC, Buttram VC: Recombinant
tissue plasminogen activator reduces adhesion formation in
a rabbit uterine horn model. Fertil Steril 51:509-512, 1989
14. Dunn RC, Steinleitner AJ, Lambert H: Synergistic
effect of intraperitoneally administered calcium channel
blockade and recombinant tissue plasminogen activator to
prevent adhesion formation in an animal model. Am J Obstet
Gynecol 164:1327-1330, 1991
15. Bothin C: Counteracting postsurgical adhesions-The effect of combined oxidized regenerated cellulose and
tissue plasminogen activator. Int J Fertil Menopausal Stud
40:102-105, 1995
16. Hill-West JL, Dunn RC, Hubbell JA: Local release of
fibrinolytic agents for adhesion prevention. J Surg Res
59:759-763, 1995
17. van Goor H, Born VJJ, van der Meer J, Sluiter WJ,
van der Schaff W, de Graaf JS, Bleichrodt RP: Pharmocokinetics of human recombinant tissue-type plasminogen activator, administered intra-abdominally, in a rat peritonitis model.
Eur Surg Res 28:287-294, 1996
18. Montz FJ, Fowler JM, Wolff AJ, Laccy SM, Mohler
M: The ability of recombinant tissue plasminogen activator
to inhibit post-radical pelvic surgery adhesions in the dog
model. Am J Obstet Gynecol 165:1539-1542, 1991

IP tPA IN RELAPSING PERITONITIS

19. Innes A, Burden RP, Finch RG, Morgan AG: Treatment of resistant peritonitis in continuous ambulatory peritoneal dialysis with intraperitoneal urokinase: A double-blind
clinical trial. Nephrol Dial Transplant 9:797-799, 1994
20. Domoto DT, Weindel ME, Blalock S, Ballal HS:
Efficacy of streptokinase in resistant, relapsing or recurrent
CAPD peritonitis. Adv Perit Dial 7:173-175, 1991
21. Murphy G, Tzamaloukas AH, Eisenberg B, Gibel LJ,
Avasthi PS: Intraperitoneal thrombolytic agents in relapsing
or persistent peritonitis of patients on continuous ambulatory peritoneal dialysis. Int J Artif Organs 14:87-91, 1991
22. Picketing SJ, Fleming SJ, Bowley JA, Sissons E
Oppenheim BA, Burnie J, Ralston AJ, Ackrill P: Urokinase:
A treatment for relapsing peritonitis due to coagulasenegative staphylococci. Nephrol Dial Transplant 4:62-65,
1989
23. Parsoo I, McIntosh CG, Seedat YK: Urokinase infusion for obstructed catheter in CAPD. Petit Dial Bull 6:105,
1986 (letter)
24. Benevent D, Peyronnet P, Brignon P, Leroux-Robert
C: Urokinase infusion for obstructed catheters and peritonitis. Petit Dial Bull 5:77, 1985 (letter)
25. Block RA, Taylor B, Frederick G: Intraperitoneal
infusion of streptokinase in the treatment of recurrent peritonitis. Petit Dial Bull 3:162-163, 1983 (letter)
26. Dasgupta MK: Use of streptokinase or urokinase in
recurrent CAPD peritonitis. Adv Perit Dial 7:169-172, 1991
27. Norris KC, Shinaberger JH, Reyes GD, Kraut JA:
The use of intracatheter installation of streptokinase in the
treatment of recurrent bacterial peritonitis in continuous
ambulatory peritoneal dialysis. Am J Kidney Dis 10:62-65,
1987
28. Tzamaloukas AH: Peritoneal fluid cell counts and
cultures in CAPD patients receiving intrapetitoneal streptokinase (urokinase) for relapsing peritonitis. Perit Dial Int
10:143-144, 1989 (letter)
29. Dasgupta MK, Bettcher KB, Ulan RA, Burns V, Lam

153

K, Dossetor JB, Costerton JW: Relationship of adherent
bacterial biofilms to peritonitis in chronic ambulatory peritoneal dialysis. Petit Dial Bull 7:168-173, 1987
30. Reid G, Khoury A, Preston C, Costerton JW: Influence of dextrose dialysis solutions on adhesion of Staphylococcus aureus and Pseudomonas aeruginosa to three catheter surfaces. Am J Nephrol 14:37-40, 1994
31. Anwar H, Dasgupta MK, Costerton JW: Testing the
susceptibility of bacteria in biofilms to antibacterial agents.
Antimicrob Agents Chemother 34:2043-2046, 1990
32. Obst G, Gagnow RE Harris A, Prentis J, Richards
GK: The activity of rifampin and analogs against Staphylococcus epidermidis biofilms in a CAPD environment model.
Am J Nephrol 9:414-420, 1989
33. Dasgupta MK, Kowalewaska-Grochowska K,
Costerton JW: Biofilm and peritonitis in peritoneal dialysis.
Petit Dial Int 13:$322-$325, 1993 (suppl 2)
34. National Kidney Foundation: DOQI Clinical Practice
Guidelines for Vascular Access. New York, NY, National
Kidney Foundation, 1997, pp 28-29
35. Weigmann TB, Stuewe B, Duncan KA, Chonko A,
Diederich DA, Grantham JJ, Savin VJ, MacDougall ML:
Effective use of streptokinase for peritoneal catheter failure.
Am J Kidney Dis 6:119-123, 1985
36. Thompson N, Uldall R: A problem in peritoneal
dialysis. Lancet 2:602-603, 1969 (letter)
37. Ladenfoged J, Steiness I: Intra-abdominal bleeding
complicating peritoneal dialysis. Lancet 1: 190, 1970 (letter)
38. Sttippoli P, Pilolli D, Mingrone G, Dimaggio A,
Coviello F, Orbello G, Querques M, Scatizzi A: A hemostasis study in CAPD patients during fibrinolytic intraperitoheal therapy with urokinase (UK). Adv Petit Dial 5:97-99,
1989
39. Gehlbach DL, O'Hair KC, Parks AL, Rosa C: Combined effects of tissue plasminogen activator and carboxymethylcellulose on adhesion reformation in rabbits. Int J
Fertil Menopausal Stud 39:172-176, 1994

